Erudio Healtherudio.com
Drug
Zipalertinib trials: what clinicians said in public
An HCP commentary report on 1 clinical trial studying zipalertinib: REZILIENT1. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| REZILIENT1 NCT04036682 · Cullinan Therapeutics Inc. | previously treated EGFR exon 20 insertion-positive metastatic NSCLC | Phase 1/Phase 2 | 155 | 56 | Standard | Nov 10, 2026 | Preview |